Gut microbiome modulates response to anti–PD-1 immunotherapy in melanoma patients
Vancheswaran GopalakrishnanDepartment of Epidemiology, Human Genetics and Environmental Sciences, University of Texas School of Public Health, Houston, TX 77030, USAC. N. SpencerDepartment of Epidemiology, Human Genetics and Environmental Sciences, University of Texas School of Public Health, Houston, TX 77030, USALuigi NeziDepartment of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USAAlexandre ReubenDepartment of Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USAMiles C. AndrewsDepartment of Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USATatiana V. KarpinetsDepartment of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USAPeter A. PrietoDepartment of Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USADiego VicenteDepartment of Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USAKristi L. HoffmanDepartment of Epidemiology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USASpencer C. WeiDepartment of Immunology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USAAlexandria P. CogdillDepartment of Immunology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USAL. ZhaoDepartment of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USACourtney W. HudgensDepartment of Translational Molecular Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USADiane S. HutchinsonDepartment of Molecular Virology and Microbiology, Baylor College of Medicine, Houston, TX 77030, USATeresa ManzoDepartment of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USAMariana Petaccia de MacêdoDepartment of Translational Molecular Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USATiziana CotechiniDepartment of Cell, Developmental and Cell Biology, Oregon Health and Sciences University, Portland, OR 97239, USATapsi KumarDepartment of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USAW. S. ChenDepartment of Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USASangeetha M. ReddyDepartment of Breast Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USARobert Szczepaniak‐SloaneDepartment of Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USAJessica Galloway-PeñaDepartment of Infectious Diseases, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USAHong JiangDepartment of Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USAP. L. ChenDepartment of Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USAElizabeth J. ShpallDepartment of Stem Cell Transplantation, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USAKatayoun RezvaniDepartment of Stem Cell Transplantation, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USAAmin M. AlousiDepartment of Stem Cell Transplantation, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USARoy F. ChemalyDepartment of Infectious Diseases, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USASamuel A. ShelburneDepartment of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USALuis M. VenceDepartment of Immunology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USAPablo C. OkhuysenDepartment of Infectious Diseases, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USAV. Behrana JensenDepartment of Veterinary Medicine and Surgery, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USAAlton G. SwennesDepartment of Molecular Virology and Microbiology, Baylor College of Medicine, Houston, TX 77030, USAFlorencia McAllisterDepartment of Clinical Cancer Prevention, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USAErick RiquelmeDepartment of Clinical Cancer Prevention, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USAYexi ZhangDepartment of Clinical Cancer Prevention, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USAEmmanuelle Le ChatelierCentre de Recherche de Jouy-en-Josas, Institut National de la Recherche Agronomique, 78352 Jouy-en-Josas, FranceLaurence ZitvogelCentre d’Investigation Clinique Biothérapie, Institut Gustave-Roussy, 94805 Villejuif Cedex, FranceNicolas PonsCentre de Recherche de Jouy-en-Josas, Institut National de la Recherche Agronomique, 78352 Jouy-en-Josas, FranceJacob L. Austin-BrenemanDepartment of Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USALauren E. HayduDepartment of Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USAElizabeth M. BurtonDepartment of Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USAJulie M. GardnerDepartment of Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USAElizabeth SirmansDepartment of Melanoma Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USAJiemiao HuDepartment of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USAAlexander J. LazarDepartment of Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USATakahiro TsujikawaDepartment of Cell, Developmental and Cell Biology, Oregon Health and Sciences University, Portland, OR 97239, USAAdi DiabDepartment of Melanoma Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USAHussein A. TawbiDepartment of Melanoma Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USAIsabella C. GlitzaDepartment of Melanoma Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USAWen-Jen HwuDepartment of Melanoma Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USASapna P. PatelDepartment of Melanoma Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USAScott E. WoodmanDepartment of Melanoma Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USARodabe N. AmariaDepartment of Melanoma Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USAMichael A. DaviesDepartment of Melanoma Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USAJeffrey E. GershenwaldDepartment of Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USAPatrick HwuDepartment of Melanoma Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USAJeffrey E. LeeDepartment of Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USAJ. ZhangDepartment of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USALisa M. CoussensDepartment of Cell, Developmental and Cell Biology, Oregon Health and Sciences University, Portland, OR 97239, USAZachary A. CooperDepartment of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USAP. Andrew FutrealDepartment of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USACarrie R. DanielDepartment of Epidemiology, Human Genetics and Environmental Sciences, University of Texas School of Public Health, Houston, TX 77030, USANadim J. AjamiDepartment of Molecular Virology and Microbiology, Baylor College of Medicine, Houston, TX 77030, USAJoseph F. PetrosinoDepartment of Molecular Virology and Microbiology, Baylor College of Medicine, Houston, TX 77030, USAMichael T. TetzlaffDepartment of Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USAPadmanee SharmaDepartment of Genitourinary Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USAJames P. AllisonDepartment of Immunology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USARobert R. JenqDepartment of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USAJennifer A. WargoDepartment of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA
2017en
ABI
Аннотация
Good bacteria help fight cancer Resident gut bacteria can affect patient responses to cancer immunotherapy (see the Perspective by Jobin). Routy et al. show that antibiotic consumption is associated with poor response to immunotherapeutic PD-1 blockade. They profiled samples from patients with lung and kidney cancers and found that nonresponding patients had low levels of the bacterium Akkermansia muciniphila . Oral supplementation of the bacteria to antibiotic-treated mice restored the response to immunotherapy. Matson et al. and Gopalakrishnan et al. studied melanoma patients receiving PD-1 blockade and found a greater abundance of “good” bacteria in the guts of responding patients. Nonresponders had an imbalance in gut flora composition, which correlated with impaired immune cell activity. Thus, maintaining healthy gut flora could help patients combat cancer. Science , this issue p. 91 , p. 104 , p. 97 ; see also p. 32
Перевод пока недоступен
Идентификаторы
Цитирования и источники
Цитирований: 6Использованных источников: 0